Literature DB >> 8669824

Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin.

N Pavlidis1, E Briassoulis, M Bai, G Fountzilas, N Agnantis.   

Abstract

The role of oncogenes in carcinoma of unknown primary site (CUP) has not yet been elucidated. In the present study the expression of the c-myc p62, ras p21 and c-erB-2 p185 oncoproteins were studied by a 3-step immunoperoxidase technique in 26 cases of CUP. Positive immunoreactivity was observed in 96% of the cases for c-myc, 92% for ras and in 65% for c-erb-2, with at least half of tumor cells labelled in 85%, 92% and 58% respectively. The degree of staining intensity was considered moderate or strong in more than half of the cases for all oncogene products. In conclusion, our results showed that patients with CUP have an extremely high overexpression of all three oncogenes studied. Nevertheless, the biological role of these overexpressed oncoproteins, their relationship with different histological or clinical parameters and their diagnostic or prognostic value need further evaluation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8669824

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

Review 1.  Progress in refining the clinical management of cancer of unknown primary in the molecular era.

Authors:  Elie Rassy; Nicholas Pavlidis
Journal:  Nat Rev Clin Oncol       Date:  2020-04-29       Impact factor: 66.675

2.  Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.

Authors:  Dimitrios Krikelis; George Pentheroudakis; Anna Goussia; Vassiliki Siozopoulou; Mattheos Bobos; Dimitrios Petrakis; Aikaterini Stoyianni; Vassilios Golfinopoulos; Andres Cervantes; Tudor Ciuleanu; George Fountzilas; Vassiliki Malamou-Mitsi; Nicholas Pavlidis
Journal:  Clin Exp Metastasis       Date:  2012-04-19       Impact factor: 5.150

3.  Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary.

Authors:  Ja Seung Koo; Haeryoung Kim
Journal:  Tumour Biol       Date:  2011-05-20

4.  [CUP syndrome: molecular pathogenesis and biology].

Authors:  A Krämer; S Gattenlöhner; K Neben
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

Review 5.  Cancers of unknown primary origin: current perspectives and future therapeutic strategies.

Authors:  Giulia Maria Stella; Rebecca Senetta; Adele Cassenti; Margherita Ronco; Paola Cassoni
Journal:  J Transl Med       Date:  2012-01-24       Impact factor: 5.531

6.  Metabolic phenotypes in primary unknown metastatic carcinoma.

Authors:  Hye Min Kim; Do Hee Kim; Woo Hee Jung; Ja Seung Koo
Journal:  J Transl Med       Date:  2014-01-06       Impact factor: 5.531

7.  Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1.

Authors:  Vasilis Karavasilis; Vasiliki Malamou-Mitsi; Evangelos Briasoulis; Elena Tsanou; Evangelia Kitsou; Haralambos Kalofonos; George Fountzilas; Theodore Fotsis; Nicholas Pavlidis
Journal:  BMC Cancer       Date:  2005-03-03       Impact factor: 4.430

8.  Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site.

Authors:  A Piga; R Nortilli; G L Cetto; N Cardarelli; S Luzi Fedeli; G Fiorentini; M D'Aprile; F Giorgi; A P Parziale; A Contu; R Montironi; R Gesuita; F Carle; R Cellerino
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

9.  Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Authors:  C Massard; J-J Voigt; A Laplanche; S Culine; A Lortholary; R Bugat; C Theodore; F Priou; M-C Kaminsky; T Lesimple; X Pivot; B Coudert; J-Y Douillard; Y Merrouche; K Fizazi
Journal:  Br J Cancer       Date:  2007-09-18       Impact factor: 7.640

10.  A multiple cavity malignancy involving the renal capsule, pleura and meninges: A case report and review of the literature.

Authors:  Li-Jing Zhu; Bao-Rui Liu; Xiao-Ping Qian; Wei-Wei Kong; Wen-Jing Hu; Juan DU; Hai-Qing Zhu
Journal:  Oncol Lett       Date:  2013-07-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.